【摘要】 应用四条引物（R₅、R₆、D₃、D₄）通过逆转录聚合酶链反应（RT-PCR）对9例急性早幼粒细胞白血病（AML-M₃）患者异基因骨髓移植（BMT）前后进行了 RAR^α/MYL 融合 mRNA 动态监测。建立的方法敏感度为0.1ng,总 RNA 相当于在10⁴～10⁵个正常细胞中检出一个 AML-M₃细胞,扩增产物的特异性经 kpnI 酶切法确认。所有9例病例中,3例于 BMT 后由阳性转阴。4例 BMT 后持续阴性表达,此7例患者均获长期无病生存。1例 BMT 后 RAR^α/MYL 融合 mRNA 持续阳性表达,最终出现白血病复发,1例失访。结果说明 RAR^α/MYL 融合 mRNA 是 AML-M₃的特异性标记,其动态检测有助于 AML-M₃患者 BMT 后残留白血病的检测,对 BMT 后白血病复发有预示价值。更多还原

【Abstract】 The RAR^α/MYL fusion transcripts were determined in bone marrow or peripheral blood samples from 9 cases of acute promyeleocytic leukemia before and after BMT by using re- verse transcripts polymerase chain reaction (RT-PCR technique.Four primers （R₅,R₆,D₃,D₄） were employed in this study.The test was able to detect the amplified RAR^α/MYL fusion tran- scripts from as little as 0.1 ng total bone marrow RNA or amount equivalent to one AML-M₃ cell per 10⁴～10⁵ normal cells.The specificity of amplified products could he further identified by Kpn I cleavage test.Seven cases showing persistent RT-PCR negative results all had long-term dis- ease-free survival,while one patient with persistent RT-PCR positivity after BMT finally had ex- tramedular relapse.We concluded that RT-PCR for RAR^α/MYL fusion mRNA was a sensitive and specific tool for monitoring minimal residual disease and for prediction of leukemia relapse in AML-M₃.更多还原